GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of a deal that pulls it close to the consumer genetics pioneer. The partners are contributing preclinical programs to a 50-50 collaboration that will use 23andMe’s genotypic and phenotypic data to accelerate progress.
{iframe}https://www.fiercebiotech.com/biotech/glaxosmithkline-makes-300m-investment-23andme-forms-50-50-r-d-pact{/iframe}